Fate Therapeutics Inc. News
This CRISPR Stock Plunged On Cell Therapy's Looming Question
A certain type of cell therapy is easier to manufacture, but may lead to worse long-term outcomes for patients.
Fate Therapeutics Stock Falls on Trial Data for Lymphoma Treatment
Fate Therapeutics falls as a trial of its B-cell lymphoma treatment produces mixed results.
Why 2018 will be better for biotech deals than 2017
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI
Here's what you need to know now for Monday, Jan. 22.
Immunotherapy stocks power higher on Celgene-Juno deal
Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.
Biotech Movers: Fate Shares Spike After Cancer Studies Progress
Fate's first subject has been treated with FATE-NK100 for AML and two additional clinical trials of FATE-NK100 for the treatment of multiple advanced solid tumor types will soon open.
Bally's Close to Making a Huge Las Vegas Strip Deal
The casino operator does not own the casino that carries its name, but changes are in the works.
New Coca-Cola Flavor is So Hip, It Comes With Its Own QR Code
Beverage giant is rolling out a new taste in its efforts to attract and keep a key demographic.
You'll Almost Have to Buy an Electric Vehicle if Climate Bill Passes
You can find savings on everything from EVs to solar panels in the Inflation Reduction Act.